Zenflow
-70%
est. 2Y upside i
Medical device that provides a more effective, less invasive…
Rank
#3499
Sector
Medical Devices
Est. Liquidity
~3Y
Data Quality
Data: LowGiven the massive preference overhang ($92.6M vs. ~$100M entry valuation), common stock equity is deeply in the money only if the company exits above $92.6M.
Last updated: July 3, 2026
IPO or category leadership drives 15x multiple on $9.8M revenue, exiting at $147M; after preference, common gains ~200% before dilution.
Revenue grows to $7.2M but multiple compresses to 6x, exit at $43.2M below $92.6M preference, leaving common stock worthless.
Revenue stagnates at $5M, multiple drops to 4x, exit at $20M, preference wipes out common.
Preference Stack Risk
severeFunding Intensity
93%Total funding $92.6M is 92.6% of estimated entry valuation $100M, leaving only $7.4M for common stock.
Dilution Risk
highThe company may need to raise additional capital within 2 years, likely diluting common shareholders by 20%.
Secondary Liquidity
noneNo secondary market data available.
Questions to Ask at the Interview
Strategic questions based on Zenflow's data — designed to show you've done your homework.
- 1
“How do you plan to compete with the established market share of UroLift and Rezūm, especially given their large sales forces?”
- 2
“What is the current 409A valuation of common stock, and how does it relate to the post-money valuation?”
- 3
“Given the data breach in January 2026, what steps are being taken to ensure patient data security and regulatory compliance?”
Community
Valuation Sentiment
Our model estimates -70% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.